logo

For the Inventor, By the Inventor

Moenchengladbach, Germany

Arman Farjam

This inventor holds 3 USPTO granted patents. Top assignee: Kali-Chemie Pharma Gmbh. Active years: 1992-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arman Farjam. Retrieved from https://idiyas.com/inventor/arman-farjam

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3

% Patents Active = 100.0

Average Co-Inventor Count = 4.7

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Wienhausen, DE (1992)
  • Moenchengladbach, DE (1996 - 1997)

Company Filing History:

goldMedal3 out of 92 
 
Kali-Chemie Pharma Gmbh
 patents

Years Active: 1992-1997

Loading Chart...
3 patents (USPTO):Explore Patents
1. 5635511 - Treatment of heart rhythm disorders by administration of (1997-06-03),
2. 5576327 - Treatment of heart rhythym disorders by administration of (1996-11-19),
3. 5164401 - Method of diuretic treatment with 3,7-diazabicyclo[3,3,1]nonane compounds (1992-11-17),

Title: Arman Farjam: Innovator in Cardiac Treatment

Introduction

Arman Farjam is a notable inventor based in Moenchengladbach, Germany. He has made significant contributions to the field of cardiac treatment through his innovative research and development of new compounds. With a total of 3 patents, Farjam is recognized for his work in addressing heart rhythm disorders.

Latest Patents

Farjam's latest patents focus on the treatment of heart rhythm disorders. One of his key inventions involves the use of 3,7,9,9-tetrasubstituted 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds for treating cardiac arrhythmias in larger mammals, including humans. Additionally, he has developed novel antiarrhythmically active compounds corresponding to a specific general formula, where R¹ is an alkyl group having 1-6 carbon atoms or a cycloalkylalkyl group having 4-7 carbon atoms.

Career Highlights

Arman Farjam is currently employed at Kali-Chemie Pharma GmbH, where he continues to advance his research in pharmacology. His work has been instrumental in developing effective treatments for cardiac conditions, showcasing his dedication to improving patient outcomes.

Collaborations

Farjam collaborates with esteemed colleagues such as Uwe Schoen and Dieter Ziegler. Their combined expertise enhances the innovative efforts within their research team.

Conclusion

Arman Farjam stands out as a significant figure in the field of cardiac treatment, with his innovative patents paving the way for advancements in medical science. His contributions are vital for the ongoing development of effective therapies for heart rhythm disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…